Monoclonal antibodies are made in a laboratory and may help our bodies fight the virus that causes COVID-19 . They are given to patients directly with an infusion or a shot. The FDA has issued EUAs for a number of investigational monoclonal antibodies.

Monoclonal Antibody Therapy Frequently Asked Questions

Updated on December 21, 2021

  • There are several different types of monoclonal antibody products.

    New data has shown that the monoclonal antibodies bamlanivimab/etesevimab (from Eli Lilly) and casirivimab/imdevimab (REGEN-COV from Regeneron) are not effective against the Omicron variant, which is currently the predominant variant in Florida.

    For this reason, Baptist Health has paused general administration of these products.

    Sotrovimab, a monoclonal antibody product made by GlaxoSmithKline, does appear to work against the Omicron variant, but at this time is in limited supply nationally.

  • At this time, Baptist Health is not administering monoclonal antibody therapy except in very limited cases of patients who are immunocompromised and meet strict medical criteria.

    The Omicron variant is currently the dominant variant in our area. Data has shown that the monoclonal antibodies bamlanivimab/etesevimab (from Eli Lilly) and casirivimab/imdevimab (REGEN-COV from Regeneron) are not effective against the Omicron variant.

    Sotrovimab, a monoclonal antibody product made by GlaxoSmithKline, does appear to work against the Omicron variant, but at this time is in limited supply nationally.

  • At this time we are not scheduling any patients to receive monoclonal antibodies at our facilities.

  • Having the COVID-19 vaccine booster helps to increase your protection against the Omicron variant. It is important to receive your booster 6 months after an mRNA vaccine, or 2 months after the one-dose Johnson & Johnson vaccine. For more information about vaccine boosters, click here.

  • At this time, Baptist Health does not have Pfizer’s Paxlovid tablets available.

    To learn more about Paxlovid, click here.